The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Biological Drug CDMO Market Research Report 2025
Synopsis
Biological drug CDMO (Contract Development and Manufacturing Organization) is a company that specializes in the development and manufacturing of biological drugs. Biological drugs are complex molecules that are produced from living cells, and they include a wide range of products such as vaccines, monoclonal antibodies, and cell therapies.
Global Biological Drug CDMO market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Biological Drug CDMO market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Biological Drug CDMO market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Samsung Biologics
Lonza
Boehringer Ingelheim
Catalent
BioCentriq
FUJIFILM Diosynth Biotechnologies
Thermo Fisher Scientific
Recipharm
Delpharm
Aenova
Siegfried
WuXi Biologics
Obio Technology
Hepalink
Pharmaron
ChemPartner
Segment by Type
Innovative Drug
Listed Patent Drugs
Biosimilar
Segment by Application
Pharmaceutical Company
Biotechnology Company
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Biological Drug CDMO report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Biological drug CDMO (Contract Development and Manufacturing Organization) is a company that specializes in the development and manufacturing of biological drugs. Biological drugs are complex molecules that are produced from living cells, and they include a wide range of products such as vaccines, monoclonal antibodies, and cell therapies.
Global Biological Drug CDMO market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Biological Drug CDMO market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Biological Drug CDMO market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Samsung Biologics
Lonza
Boehringer Ingelheim
Catalent
BioCentriq
FUJIFILM Diosynth Biotechnologies
Thermo Fisher Scientific
Recipharm
Delpharm
Aenova
Siegfried
WuXi Biologics
Obio Technology
Hepalink
Pharmaron
ChemPartner
Segment by Type
Innovative Drug
Listed Patent Drugs
Biosimilar
Segment by Application
Pharmaceutical Company
Biotechnology Company
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Biological Drug CDMO report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biological Drug CDMO Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Innovative Drug
1.2.3 Listed Patent Drugs
1.2.4 Biosimilar
1.3 Market by Application
1.3.1 Global Biological Drug CDMO Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biological Drug CDMO Market Perspective (2018-2029)
2.2 Biological Drug CDMO Growth Trends by Region
2.2.1 Global Biological Drug CDMO Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Biological Drug CDMO Historic Market Size by Region (2018-2023)
2.2.3 Biological Drug CDMO Forecasted Market Size by Region (2024-2029)
2.3 Biological Drug CDMO Market Dynamics
2.3.1 Biological Drug CDMO Industry Trends
2.3.2 Biological Drug CDMO Market Drivers
2.3.3 Biological Drug CDMO Market Challenges
2.3.4 Biological Drug CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biological Drug CDMO Players by Revenue
3.1.1 Global Top Biological Drug CDMO Players by Revenue (2018-2023)
3.1.2 Global Biological Drug CDMO Revenue Market Share by Players (2018-2023)
3.2 Global Biological Drug CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Biological Drug CDMO Revenue
3.4 Global Biological Drug CDMO Market Concentration Ratio
3.4.1 Global Biological Drug CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biological Drug CDMO Revenue in 2022
3.5 Biological Drug CDMO Key Players Head office and Area Served
3.6 Key Players Biological Drug CDMO Product Solution and Service
3.7 Date of Enter into Biological Drug CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Biological Drug CDMO Breakdown Data by Type
4.1 Global Biological Drug CDMO Historic Market Size by Type (2018-2023)
4.2 Global Biological Drug CDMO Forecasted Market Size by Type (2024-2029)
5 Biological Drug CDMO Breakdown Data by Application
5.1 Global Biological Drug CDMO Historic Market Size by Application (2018-2023)
5.2 Global Biological Drug CDMO Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Biological Drug CDMO Market Size (2018-2029)
6.2 North America Biological Drug CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Biological Drug CDMO Market Size by Country (2018-2023)
6.4 North America Biological Drug CDMO Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biological Drug CDMO Market Size (2018-2029)
7.2 Europe Biological Drug CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Biological Drug CDMO Market Size by Country (2018-2023)
7.4 Europe Biological Drug CDMO Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biological Drug CDMO Market Size (2018-2029)
8.2 Asia-Pacific Biological Drug CDMO Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Biological Drug CDMO Market Size by Region (2018-2023)
8.4 Asia-Pacific Biological Drug CDMO Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biological Drug CDMO Market Size (2018-2029)
9.2 Latin America Biological Drug CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Biological Drug CDMO Market Size by Country (2018-2023)
9.4 Latin America Biological Drug CDMO Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biological Drug CDMO Market Size (2018-2029)
10.2 Middle East & Africa Biological Drug CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Biological Drug CDMO Market Size by Country (2018-2023)
10.4 Middle East & Africa Biological Drug CDMO Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Samsung Biologics
11.1.1 Samsung Biologics Company Detail
11.1.2 Samsung Biologics Business Overview
11.1.3 Samsung Biologics Biological Drug CDMO Introduction
11.1.4 Samsung Biologics Revenue in Biological Drug CDMO Business (2018-2023)
11.1.5 Samsung Biologics Recent Development
11.2 Lonza
11.2.1 Lonza Company Detail
11.2.2 Lonza Business Overview
11.2.3 Lonza Biological Drug CDMO Introduction
11.2.4 Lonza Revenue in Biological Drug CDMO Business (2018-2023)
11.2.5 Lonza Recent Development
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Detail
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Biological Drug CDMO Introduction
11.3.4 Boehringer Ingelheim Revenue in Biological Drug CDMO Business (2018-2023)
11.3.5 Boehringer Ingelheim Recent Development
11.4 Catalent
11.4.1 Catalent Company Detail
11.4.2 Catalent Business Overview
11.4.3 Catalent Biological Drug CDMO Introduction
11.4.4 Catalent Revenue in Biological Drug CDMO Business (2018-2023)
11.4.5 Catalent Recent Development
11.5 BioCentriq
11.5.1 BioCentriq Company Detail
11.5.2 BioCentriq Business Overview
11.5.3 BioCentriq Biological Drug CDMO Introduction
11.5.4 BioCentriq Revenue in Biological Drug CDMO Business (2018-2023)
11.5.5 BioCentriq Recent Development
11.6 FUJIFILM Diosynth Biotechnologies
11.6.1 FUJIFILM Diosynth Biotechnologies Company Detail
11.6.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.6.3 FUJIFILM Diosynth Biotechnologies Biological Drug CDMO Introduction
11.6.4 FUJIFILM Diosynth Biotechnologies Revenue in Biological Drug CDMO Business (2018-2023)
11.6.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.7 Thermo Fisher Scientific
11.7.1 Thermo Fisher Scientific Company Detail
11.7.2 Thermo Fisher Scientific Business Overview
11.7.3 Thermo Fisher Scientific Biological Drug CDMO Introduction
11.7.4 Thermo Fisher Scientific Revenue in Biological Drug CDMO Business (2018-2023)
11.7.5 Thermo Fisher Scientific Recent Development
11.8 Recipharm
11.8.1 Recipharm Company Detail
11.8.2 Recipharm Business Overview
11.8.3 Recipharm Biological Drug CDMO Introduction
11.8.4 Recipharm Revenue in Biological Drug CDMO Business (2018-2023)
11.8.5 Recipharm Recent Development
11.9 Delpharm
11.9.1 Delpharm Company Detail
11.9.2 Delpharm Business Overview
11.9.3 Delpharm Biological Drug CDMO Introduction
11.9.4 Delpharm Revenue in Biological Drug CDMO Business (2018-2023)
11.9.5 Delpharm Recent Development
11.10 Aenova
11.10.1 Aenova Company Detail
11.10.2 Aenova Business Overview
11.10.3 Aenova Biological Drug CDMO Introduction
11.10.4 Aenova Revenue in Biological Drug CDMO Business (2018-2023)
11.10.5 Aenova Recent Development
11.11 Siegfried
11.11.1 Siegfried Company Detail
11.11.2 Siegfried Business Overview
11.11.3 Siegfried Biological Drug CDMO Introduction
11.11.4 Siegfried Revenue in Biological Drug CDMO Business (2018-2023)
11.11.5 Siegfried Recent Development
11.12 WuXi Biologics
11.12.1 WuXi Biologics Company Detail
11.12.2 WuXi Biologics Business Overview
11.12.3 WuXi Biologics Biological Drug CDMO Introduction
11.12.4 WuXi Biologics Revenue in Biological Drug CDMO Business (2018-2023)
11.12.5 WuXi Biologics Recent Development
11.13 Obio Technology
11.13.1 Obio Technology Company Detail
11.13.2 Obio Technology Business Overview
11.13.3 Obio Technology Biological Drug CDMO Introduction
11.13.4 Obio Technology Revenue in Biological Drug CDMO Business (2018-2023)
11.13.5 Obio Technology Recent Development
11.14 Hepalink
11.14.1 Hepalink Company Detail
11.14.2 Hepalink Business Overview
11.14.3 Hepalink Biological Drug CDMO Introduction
11.14.4 Hepalink Revenue in Biological Drug CDMO Business (2018-2023)
11.14.5 Hepalink Recent Development
11.15 Pharmaron
11.15.1 Pharmaron Company Detail
11.15.2 Pharmaron Business Overview
11.15.3 Pharmaron Biological Drug CDMO Introduction
11.15.4 Pharmaron Revenue in Biological Drug CDMO Business (2018-2023)
11.15.5 Pharmaron Recent Development
11.16 ChemPartner
11.16.1 ChemPartner Company Detail
11.16.2 ChemPartner Business Overview
11.16.3 ChemPartner Biological Drug CDMO Introduction
11.16.4 ChemPartner Revenue in Biological Drug CDMO Business (2018-2023)
11.16.5 ChemPartner Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
